A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma
Pediatric Blood & Cancer2016Vol. 63(8), pp. 1349–1356
Citations Over TimeTop 10% of 2016 papers
Judith G. Villablanca, Samuel L. Volchenboum, Hwangeui Cho, Min H. Kang, Susan L. Cohn, Clarke P. Anderson, Araz Marachelian, Susan Groshen, Denice Tsao‐Wei, Katherine K. Matthay, John M. Maris, Charlotte E. Hasenauer, Scarlett Czarnecki, Hollie Lai, Fariba Goodarzian, Hiro Shimada, C. Patrick Reynolds
Abstract
BSO (75 gram/m(2) ) with melphalan (125 mg/m(2) ) is tolerable with stem cell support and active in recurrent/refractory neuroblastoma. Further dose escalation is feasible and may increase responses.
Related Papers
- Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.(1984)
- → Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine(1991)12 cited
- Determination fudosteine in plasma and its pharmacokinetics by LC-MS(2008)
- Study on Pharmacokinetics and Pharmacodynamics of Pazufloxacin Mesilate in Healthy Volunteers(2008)
- Pharmacokinetics study of lansoprazole for injection in Chinese healthy volunteers(2011)